Oncology Corporate Profile
CureVac is the global leader in mRNA based vaccination technologies and develops mRNAbased vaccines as therapeutic vaccines in oncology as well as prophylactic vaccines for infectious diseases. The company has completed Phase I/IIa studies with cancer vaccines based on its RNActive® technology platform for the treatment of prostate cancer and nonsmall cell lung cancer (NSCLC). In addition, CureVac also independently develops RNActive® prophylactic vaccines against various infectious diseases. The company has also developed RNA-based adjuvants. Results with these CureVac products strongly suggest that they are safe and capable of inducing balanced immune responses including humoral and cellular, Th1 and Th2 and effector and memory responses.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|CV9201||immunotherapy||1st line metastatic Non Small cell Lung Cancer (NSCLC)||II|
|CV9103||immunotherapy||Castrate-resistant Prostate cancer (CRPC)||II|
View additional information on product candidates here »